Treatment of human umbilical cord-derived mesenchymal stem cells for hepatitis B virus-associated decompensated liver cirrhosis: A clinical trial

Table 1 Summary of adverse event

Characteristics		Low-dose group (n = 8)	Medium-dose group (n = 8)	High-dose group (n = 8)	F value	P value
Total adverse event		63	34	54	-	-
Severity of AE	Class 1	33	18	24	2.341	0.2101
	Class 2	24	10	16
	Class 3	6	5	13
	Class 4	0	1	1
Association with hUC-MSCs	Absolutely relevant	0	0	0	1.262	0.3435
	Possibly relevant	4	0	0
	Possibly irrelevant	1	1	0
	Absolutely irrelevant	58	33	54
AE led to reduce dosage		0	0	0	-	-
AE led to terminate therapy		0	0	0	-	-
AE led to death		0	0	0	-	-

This table excludes the severe adverse event. AE: Adverse event; hUC-MSCs: Human umbilical cord-derived mesenchymal stem cells.